Top 5 Long Term Stocks To Watch Right Now

L&T Infra bonds will have a lock-in period of five years. Post five years, these bonds will be traded on BSE. At the same time, the company can also exercise the buyback option. The buyback option can be exercised both at the end of five years and seven years. Bond investors will get the income tax benefits under 80CCF wherein a maximum investment of Rs 20,000 would fetch tax exemptions to the tune of Rs 2,060 (10.3% of 20,000) - minimum and 6,180 (30.9% of 20,000) - maximum. L&T Infrastructure Finance is looking to raise at least Rs 300 crore by way of issuing the second tranche of tax-saving bonds in the current financial year. The company has already collected Rs 530 crs in the first tranche in November 2011. The interest rates are lower than the previous issue as the coupon rates have to be at par with the yield on benchmark securities, and the decrease is in sync with the yield movement over the last month.

Recommendation: We believe that the tax saving bond issue from L&T Infra is a good long term investment opportunity as well as a tax saving instrument for investors. As the interest rates are at the peak and the rates are expected to go down this is the best time to enter in the bond market and lock in investments at a higher rate.

Best Construction Companies To Buy Right Now: Douglas Emmett Inc. (DEI)

Douglas Emmett, Inc., a real estate investment trust, owns and operates office and multifamily properties in California and Hawaii. As of December 31, 2007, the company�s office portfolio consisted of 48 properties and multifamily portfolio consisted of 9 properties. Its properties are located in Brentwood, Olympic Corridor, Century City, Beverly Hills, Santa Monica, Westwood, Sherman Oaks/Encino, Warner Center/Woodland Hills, and Burbank submarkets of Los Angeles County, California, as well as in Honolulu, Hawaii. The company is headquartered in Santa Monica, California.

Advisors' Opinion:

• [By Rich Duprey]

  Office and multifamily housing operator�Douglas Emmett� (NYSE: DEI  ) �announced yesterday�its second-quarter dividend of $0.18 per share, the same rate it's paid for the last two quarters after raising the payout 20% from $0.15 per share.

Top 5 Long Term Stocks To Watch Right Now: Rubicon Minerals Corp(RBY)

Rubicon Minerals Corporation, a mineral exploration company, engages in the acquisition, exploration, and development of mineral properties in Canada and the United States. It primarily explores for gold and base metal deposits. The company?s key asset is the Phoenix Gold Project located in the Red Lake gold camp, in the Province of Ontario. As of March 31, 2010, it controlled approximately 65,000 acres of prime exploration ground in the prolific Red Lake gold district of Ontario, Canada, as well as approximately 380,000 acres surrounding the Pogo Mine in Alaska and approximately 225,000 acres in northeast Nevada. The company was founded in 1996 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Sean Williams]

  Another reason this fund looks attractive (at least to me) is that Rubicon Minerals (NYSEMKT: RBY  ) is one of its largest holdings at 6.02% of its assets as of May 10, 2013. Rubicon is in the late stages of the development process for the F2 Gold System, which has yielded drilling assessments as high as 767 grams/ton. F2 appears to be just as bountiful in gold well below the surface as it is near the surface, which could mean a very long and profitable mine life for Rubicon.

Top 5 Long Term Stocks To Watch Right Now: Affymetrix Inc.(AFFX)

Affymetrix, Inc. engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets primarily in the United States, Europe, Japan. The company provides integrated GeneChip microarray platform, which includes disposable DNA probe arrays (chips) consisting of nucleic acid sequences, certain reagents for use with the probe arrays, a scanner and other instruments used to process the probe arrays, and software to analyze and manage genomic or genetic information obtained from the probe arrays. It also offers GeneTitan, an instrument system that runs genotyping and gene expression array plates; and GeneAtlas, an instrument for low-to-medium throughput that provides hybridization and array processing with microwell-based labware, as well as a line of multiplex assays to serve the discovery and the validation markets. In addition, the company provides reagent kits, including ExoSAP-IT fo r a reagent for the clean-up of polymerase chain reaction (PCR) products used in downstream applications, such as DNA sequencing or single-nucleotide polymorphisms analysis; and HotStart-IT reagents that utilize a novel primer binding protein to inhibit primer dimer formation with results in sensitive and consistent amplification for PCR. Its products are used primarily in genotyping and gene expression applications. The company sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies; academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe, as well as through life science supply specialists acting as authorized distributors in Latin America, the Middle East, and Asia Pacific regions. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

Advisors' Opinion:

• [By Ben Levisohn]

  Taser has dropped 4% this morning after gaining 33% during the past month. That gain would have put it in the top-ten in the S&P 1500 if it were a member of� the index, behind Questcor Pharmaceuticals (QCOR), which has gained 36%, healthcare company Amedisys (AMED) and Affymetrix (AFFX), which has gained 44%, among others.

• [By Monica Gerson]

  Breaking news

  Acceleron Pharma (NASDAQ: XLRN) today announced that it has commenced an underwritten public offering of $100 million of its common stock. To read the full news, click here. XenoPort (NASDAQ: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. To read the full news, click here. Affymetrix (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan庐 Dx Assay. To read the full news, click here. Verizon Communications (NYSE: VZ) and Intel (NASDAQ: INTC) today announced an agreement for Verizon to purchase from Intel the assets of Intel Media, a business division dedicated to the development of Cloud TV products and services. To read the full news, click here.

  Posted-In: Evercore Partners US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

• [By James E. Brumley]

  Every year, more than 100,000 white papers on the topic of cancer and cancer treatments are published. Right now, there are over 500 new cancer drugs in development, and those therapies are part of more than 10,000 different clinical trials currently underway. That's all in addition to the already-approved cancer drugs, and the volumes of information we already know about oncology. What's it mean? It means the cancer-treating energy often suffers from information overload, which in turn means patients aren't getting the best care they could get. The solution is a tool built by a little company called CollabRx Inc. (NASDAQ:CLRX). The validation for that solution comes from much bigger companies Quest Diagnostics Inc. (NYSE:DGX) and Affymetrix, Inc. (NASDAQ:AFFX).

• [By Rich Duprey]

  It's in the genes
  Elsewhere in the market, however,�Affymetrix (NASDAQ: AFFX  ) tumbled more than 13% after preannouncing first-quarter earnings that missed even its own expectations. It blamed "headwinds" in its gene expression business everywhere it does business, though it suffered a particular shortfall in Japan. The Fool's Sean Williams thinks that may indicate more than a one-off performance issue because of the global nature of the miss Affymetrix suffered.

Top 5 Long Term Stocks To Watch Right Now: Genomma Lab Internacional SAB de CV (LABB.MX)

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company�� product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. Advisors' Opinion:

• [By Ben Levisohn]

  He then took a deep dive into Genomma Lab�(LABB.MX), a Mexican producer of over-the counter pharmaceuticals, generic drugs, and personal care products. Now, I’m sitting with a Chromebook in a large auditorium, so I hope I’ve captured the essence of his argument.